Vanflyta
Payments companies reported to CMS as associated with Vanflyta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vanflyta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vanflyta
These are the largest totals companies reported as associated with Vanflyta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Harry Erba | Ann Arbor, MI | Medical Oncology | $66,706.18 |
| Naval Daver | Houston, TX | Hematology & Oncology | $50,620.57 |
| Mikkael Sekeres | Miami, FL | Hematology & Oncology | $23,221.19 |
| Hetty Carraway | Chagrin Falls, OH | Hematology & Oncology | $21,185.33 |
| Elias Jabbour | Houston, TX | Hematology & Oncology | $20,603.84 |
| Uma Borate | Columbus, OH | Hematology (Internal Medicine) | $18,783.21 |
| Joshua Zeidner | Chapel Hill, NC | Hematology & Oncology | $18,433.82 |
| Catherine Smith | San Francisco, CA | Internal Medicine | $18,291.57 |
| Alexander Perl | Philadelphia, PA | Medical Oncology | $17,493.43 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $15,909.80 |
Prescribed Vanflyta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.